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Abstract
Background: Activation of telomerase resulting from deregulated hTERT expression is a key event during high-risk 
human papillomavirus (hrHPV)-induced cervical carcinogenesis. In the present study we examined hTERT promoter 
activity and its relation to DNA methylation as one of the potential mechanisms underlying deregulated hTERT 
transcription in hrHPV-transformed cells.
Methods: Using luciferase reporter assays we analyzed hTERT promoter activity in primary keratinocytes, HPV16- and 
HPV18-immortalized keratinocyte cell lines and cervical cancer cell lines. In the same cells as well as cervical specimens 
we determined hTERT methylation by bisulfite sequencing analysis of the region spanning -442 to +566 (relative to the 
ATG) and quantitative methylation specific PCR (qMSP) analysis of two regions flanking the hTERT core promoter.
Results: We found that in most telomerase positive cells increased hTERT core promoter activity coincided with 
increased hTERT mRNA expression. On the other hand basal hTERT promoter activity was also detected in telomerase 
negative cells with no or strongly reduced hTERT mRNA expression levels. In both telomerase positive and negative 
cells regulatory sequences flanking both ends of the core promoter markedly repressed exogenous promoter activity.
By extensive bisulfite sequencing a strong increase in CpG methylation was detected in hTERT positive cells compared 
to cells with no or strongly reduced hTERT expression. Subsequent qMSP analysis of a larger set of cervical tissue 
specimens revealed methylation of both regions analyzed in 100% of cervical carcinomas and 38% of the high-grade 
precursor lesions, compared to 9% of low grade precursor lesions and 5% of normal controls.
Conclusions: Methylation of transcriptionally repressive sequences in the hTERT promoter and proximal exonic 
sequences is correlated to deregulated hTERT transcription in HPV-immortalized cells and cervical cancer cells. The 
detection of DNA methylation at these repressive regions may provide an attractive biomarker for early detection of 
cervical cancer.
Background
Telomerase is a ribonucleoprotein with reverse tran-
scriptase activity that adds hexameric TTAGGG repeats
onto the telomeric ends of chromosomes. Thereby it
compensates for telomere shortening that is inherent to
DNA replication, the so-called end replication problem
[1]. Telomerase activation is a key feature of human can-
cers. The telomerase complex consists of several sub-
units, including a structural RNA component (hTR) that
serves as a template during telomere elongation [2] and a
catalytic subunit (hTERT) [3]. hTR is ubiquitously
expressed and frequently elevated in cancer cells [4].
Expression of hTERT is restricted to telomerase positive
cells [3], indicating that hTERT expression controls
telomerase activity. Indeed, ectopic expression of hTERT
is sufficient for the activation of telomerase in telomerase
negative cells [5].
The hTERT gene has a CG-rich, TATA-less promoter,
within which a proximal region of 200 base pairs has been
identified as the core promoter, being indispensable for
transcription activation [6,7]. This core sequence con-
tains numerous binding sites for both transcriptional
activators and repressors [6,8-10].
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Page 2 of 14The fact that the 5' region of the hTERT gene and its
promoter are part of a large ~4 kb CpG island (-1800 to
+2200, numbered relative to the ATG) implies that
hTERT expression may be responsive to CpG methyla-
tion [8]. To evaluate this possible regulatory mechanism,
several groups have assessed the methylation status of the
hTERT CpG island in a variety of primary cells as well as
immortal and cancer cell lines [11-17]. In embryonic
stem cells and normal lymphocytes, which express
hTERT, almost all CpGs around the transcription start
site of the hTERT gene are unmethylated [17]. However,
hTERT expression is not always associated with hypom-
ethylation. In many cancer cell lines hTERT expression is
often correlated with hypermethylation [11,14], although
the expression level in these cells is usually much lower
than in ES cells [17]. Other studies did not find a clear
correlation between hTERT methylation and hTERT
expression [12,13]. Zinn et al. [17] showed that in most
cancer cell lines the hTERT promoter is densely methy-
lated, but that CpGs around the transcription start site of
a substantial number of hTERT alleles is unmethylated.
This suggests that methylation of hTERT promoters is
heterogeneous and that only unmethylated alleles are
expressed. Indeed, histones at a hypomethylated core-
promoter carry transcription active marks (H3K9Ac and
H3K4 me2) whereas a methylated core-promoter carries
inactive marks (H3K9 me3 and H3K27 me3) [17]. The
importance of this core promoter region is also illustrated
by the observation that sequences surrounding the
hypomethylated and active core promoter may be hyper-
methylated [18]. In addition to the importance of the
methylation status of the core-promoter region, other
sequences in hTERT CpG island may also be important.
Choi et al. [11] observed in colorectal cancer hypermeth-
ylation of a specific CpG outside known transcription
factor binding sites, that together with hypermethylation
of a number of CpGs closer to the transcription start site
was associated with increased hTERT expression. It is
unknown how methylation of these CpGs induce hTERT
expression. The CpG rich region encompassing the 5'
proximal region of the gene has also been shown to affect
hTERT expression [18]. This region binds the transcrip-
tional repressor CTCF and in cancer cells CTCF repres-
sion was shown to be relieved by methylation of its
binding site. A second CTCF binding site has been identi-
fied in exon 2 [18]. Thus, aberrant methylation of the 5'
end of gene, including CTCF sites, can affect hTERT
expression.
Despite the fact that deregulated hTERT expression is
implicated in human papillomavirus (HPV)-mediated
pathogenesis of cervical cancer, little is known about the
mechanism and whether it also involves changes in CpG
methylation.
Infection with high-risk human papillomavirus
(hrHPV) has been recognized as the main risk factor for
the development of cervical cancer, which is supported by
the detection of hrHPV in virtually all cervical carcino-
mas [19,20]. HrHPV activities together with host cell fac-
tors are required for the progression of hrHPV-induced
precancerous lesions to invasive cancer.
Our previous studies showed elevated hTERT mRNA
levels and increased telomerase activity in over 90% of
cervical carcinomas and less than half of high-grade pre-
cursor lesions, so-called cervical intraepithelial neopla-
sias (CINs). Most normal cervical tissues and low-grade
CIN lesions were devoid of detectable hTERT mRNA and
telomerase activity [21]. These findings indicate that ele-
vated levels of hTERT mRNA reflect a late step in the
CIN to carcinoma sequence following hrHPV infection. It
is conceivable that telomerase-positive CIN lesions have
gained an immortal phenotype and have reached a point
of no return in terms of malignant potential. Ectopic
expression of HPV16 E6, along with E6AP can, (in part)
mediated by c-Myc, induce hTERT transcription and
telomerase activity directly [22-24].
Additionally, E6 associated with E6AP can degrade the
hTERT repressor NFX1-91, which normally interacts
with the co-repressor complex mSin3A/histone deacety-
lase (HDAC) at the hTERT promoter [25]. By degrading
NFX1-91, E6/E6AP changes the chromatin structure at
the hTERT promoter which results in increased hTERT
expression [26]. More recently, NFX1-123, which like
NFX1-91 is a splice variant of NFX1, has been demon-
strated to increase hTERT expression posttranscription-
ally in HPV E6 containing keratinocytes [27].
However, several other studies have shown that in the
context of the whole HPV genome, E6 activity alone is
insufficient for increasing hTERT expression and con-
comitant telomerase activation in human keratinocytes
[28,29]. Microcell-mediated chromosome transfer studies
have shown that the increased hTERT mRNA expression
and telomerase activity in HPV-immortalized cells and
cervical cancer cells may depend on a recessive event,
suggesting inactivating alterations of host cell genes being
involved in this process as well [29-31]. We previously
demonstrated that potential hTERT regulatory genes
reside on chromosome 6q, which may either directly or
indirectly regulate hTERT transcription [5,32].
In the present study we aimed to directly assess the
activity of the regulatory hTERT sequences in HPV-
transformed cells and the potential role of hTERT methy-
lation in cervical carcinogenesis. To this end, we first ana-
lyzed the activity of various hTERT promoter and
proximal exonic/intronic sequences by transient
luciferase reporter assays in four human keratinocyte cell
lines, immortalized by full-length HPV16 and HPV18
DNA, and three cervical cancer cell lines. Secondly, we
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methylation-specific PCR (qMSP) to examine hTERT
DNA methylation in all cell lines as well as cervical tissue
specimens representing the complete spectrum of (pre-
)malignant disease.
Methods
Cells and cell lines
Primary keratinocytes (EK94-2 and EK04-3) were iso-
lated from human foreskins, as described before [29]. The
cell lines FK16A, FK16B, and FK18A and FK18B were
established by transfection of primary foreskin keratino-
cytes with the entire HPV16 and HPV18 genomes,
respectively [29]. The cervical carcinoma cell lines SiHa
(HPV16), HeLa (HPV18) and CaSki (HPV16), were
obtained from the American Type Culture Collection
(Manassas, VA). Culture conditions for these cells and
cell lines were described previously [29,33].
The hTERT-negative osteosarcoma cell line Saos-2 was
obtained from American Type Culture Collection
(Manassas, VA) and cultured in Dulbecco's modified
Eagle medium (DMEM) supplemented with 10% foetal
bovine serum (FBS), penicillin (100 U/mL), streptomycin
(100 μg/mL), and L-glutamine (2 mM) (all from Life
Technologies, Inc., Breda, The Netherlands).
Clinical samples
Formalin fixed, paraffin-embedded biopsies of normal
cervix (n = 22), CIN1 lesions (n = 26), CIN3 lesions (n =
29) and cervical squamous cell carcinomas (SCCs) (n =
21) were collected during routine clinical practice and
stored at the Department of Pathology of the VU Univer-
sity Medical Center. Cervical scrapings analyzed by
bisulfite sequencing analysis were collected from women
taking part in a population-based cervical screening trial
[34]. We included three scrapings of women without CIN
disease (classified as normal cytology n = 2, and border-
line mild dyskaryosis n = 1) and one scrape (classified as
moderate dyskaryosis) of a woman with CIN disease.
HPV DNA presence was determined using GP5+/6+-
PCR, followed by an enzyme immunoassay (EIA) with
cocktail probes representing pools of high- and low-risk
HPV types, respectively [35]. Subsequently, HPV typing
was performed on PCR products of EIA-positive cases
using reverse line blot (RLB) analysis, as described previ-
ously [36]. EIA-positive samples that failed to reveal an
RLB signal, were considered to contain HPV (sub)types
or variants that do not react with the specific RLB probes
and these HPVs were referred to as HPV X (X). All cervi-
cal scrapings, 7 CIN 1 lesions, all except one CIN3
lesions, and all SCCs were hrHPV-positive by GP5+/6+-
PCR. None of the normal biopsies was hrHPV-positive.
This study was approved by the Institutional Review
Board of the VU University Medical Center. Cervical
scrapings were obtained from the population-based cer-
vical screening trial POBASCAM, registered as an Inter-
national Standard Randomized Controlled Trial under
number ISRCTN20781131 [34].
RNA isolation and quantitative RT-PCR
Total RNA was isolated from cell lines using RNA Bee
(Tel-test, Friendswood, TX) following the manufacturer's
instructions. hTERT mRNA was quantified by real time
RT-PCR using the TeloTAGGG hTERT kit (Roche,
Woerden, The Netherlands), according to the manufac-
turer's manual. Relative hTERT levels were determined by
dividing hTERT expression levels by expression levels of
the housekeeping gene Porphobilinogen Deaminase
(PBGD), which was also included in the TeloTAGGG
hTERT kit (Roche). hTERT levels were considered to be
low when the ratio between hTERT and PBGD expres-
sion was < 1. All PCR reactions were performed in dupli-
cate and mean values including the standard deviation
were calculated.
hTERT promoter constructs
The pGL3-control vector (Promega Benelux BV, Leiden,
The Netherlands) contains the Firefly luciferase gene
under the control of a CMV promoter. The pGL3-basic
vector (Promega Benelux BV) is a promoterless vector
containing the Firefly luciferase gene. The hTERT
reporter constructs contain DNA fragments of the
hTERT promoter inserted upstream of the Firefly
luciferase gene in the pGL3 basic vector.
hTERT-1821/-23, hTERT-499/-23, hTERT-297/-23,
hTERT-297/+81, and hTERT-297/+357, which contain
hTERT promoter sequences from -1821 bp to -23 bp, -
499 to -23 bp, -297 to -23 bp, -297 to +81 bp, and -297 to
+357 bp, respectively, relative to the ATG start site, have
previously been referred to as pTERT-1821, pTERT-499,
pTERT-297, pTERT-297/ex1 mini, and pTERT-297/ex1
[18,37] and were kindly provided by Dr. J. Benhattar
(Institute of Pathology, Centre Hospitalier Universitaire
Vaudois, Lausanne, Switzerland).
Transfection and luciferase assay
Cells were seeded on 48 wells plates at a concentration of
10,000 cells/well (SiHa, HeLa and CaSki) or 20.000 cells/
well (EK04-3, FK16A, FK16B, FK18A, and FK18B) and
cultured overnight. Transient transfection of luciferase
reporter plasmids was performed using TransPEI (Euro-
gentec, Seraing, Belgium) according to the manufac-
turer's protocol. The Renilla luciferase reporter vector
(Promega Benelux BV) was co-transfected as an internal
control for transfection efficiency. Briefly, cells were
exposed to a transfection mixture containing 500 ng of
reporter plasmid and 25 ng of internal control for 4 hours
at 37°C.
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Luciferase assays were performed using the Dual
Luciferase Reporter Assay System (Promega Benelux BV)
and a Lumat LB 9507 luminometer (EG&G Berthold, Bad
Wildbad, Germany). For calculations the mean values of
relative luciferase activity, i.e. Firefly luciferase divided by
Renilla luciferase activity, were used, in which the mean
relative luciferase activity of the pGL3 control vector was
set at 100%. All experiments were performed (at least) in
duplicate and mean values including standard deviation
were calculated.
DNA isolation and bisulfite modification
Genomic DNA from cultured cells was isolated using
DNA STAT-60 (Tel-Test, Friendswood, TX). Genomic
DNA from paraffin-embedded tissue specimens was iso-
lated as described previously [38]. Ten paraffin-embed-
ded tissue sections of 5 μm were digested in 450 μL
proteinase K buffer [100 mmol/L Tris-HCl (pH 9.0), 10
mmol/L NaCl, 1% SDS, and 5 mmol/L EDTA] with 50 μL
Proteinase K (1 mg/mL; Boehringer-Ingelheim, Alkmaar,
The Netherlands) for 24 hours at 52°C with shaking.
Thereafter, DNA was isolated by phenol/chloroform/iso-
amylalcohol (25:24:1) extraction, followed by ethanol pre-
cipitation. DNA was dissolved in H2O. The histology of
sections used for DNA isolation was checked according
to the sandwich method in which the first and last section
were stained by H&E and checked by a pathologist for
presence of the lesion. Tumor sections contained in gen-
eral 50-80% of tumor cells, whereas sections of CIN
lesions contained 10-50% of dysplastic cells.
Genomic DNA of cervical scrapings was isolated using
the high pure PCR template preparation kit (HPPTP,
Roche, Mannheim, Germany). After a classic cervical
smear was made on a slide, cervical scrapes were col-
lected by placing the brush in 5 ml sterile phosphate-buff-
ered saline (PBS, 0.82% (w/v); NaCl, 0.19% (w/v);
Na2HPO4·2H2O,·0.03% (w/v); NaH2PO4·2H2O, adjusted
to pH 7.4 with HCl) 0.005% merthiolate. Upon arrival in
the laboratory, cells were pelleted at 300 g for 10 min and
resuspended in 1 ml 10 mM Tris-HCl (pH 7.4). A 100-μl
Tris-HCl suspension was used for DNA isolation by the
HPPTP kit (Roche) according to the recommendations of
the manufacturer, except that samples were eluted with
100 μl of elution buffer. Ultimately, 10 μl of eluate was
used for HPV detection and 500 ng of DNA for bisulfite
modification.
Sodium bisulfite modification, which induces chemical
conversion of unmethylated cytosines into uracils,
whereas methylated cytosines are protected from this
conversion, was performed using the EZ DNA Methyla-
tion Kit, according to the manufacturer's guidelines
(Zymo Research, Orange, CA).
Bisulfite sequencing
The hTERT promoter and first exon were amplified using
4 primer sets spanning the hTERT promoter and coding
sequence from -442 to +566 bp, relative to the ATG start
codon (Table 1). All primers have been previously
described by Guilleret et al. [39], but were in some cases
used in a different combination.
The PCR mixtures contained 50 ng of modified DNA,
0.5 μM primers, 200 μM dNTPs, 1.5 mM MgCl2 and 1 U
of FastStart Taq DNA polymerase (Roche). Amplification
conditions were: denaturation at 95°C for 4 minutes; 40
cycles of 95°C for 1 minute, 60°C for 1 minute and 72°C
for 1 minute; and a final elongation step of 72°C for 4
minutes. Subsequently, PCR products were purified using
a QIAgen PCR purification kit (Westburg, Leusden, The
Netherlands) and cloned in pGEM-T using the pGEM-T
Easy Cloning kit (Promega). For most regions, between
10 and 20 cloned PCR fragments were sequenced using
the BigDye Terminator v1.1 Cycle Sequencing Kit on an
ABI Prism Avant Genetic Analyzer (Applied Biosystems,
Nieuwerkerk a/d IJssel, The Netherlands) and sequences
were analyzed using Vector NTI (Invitrogen, Breda, The
Netherlands).
Quantitative methylation-specific PCR (qMSP)
qMSP was performed using two primer and Taqman
probe combinations, one of which was located in the pro-
moter (region 1) and the other in the first intron and exon
2 (region 2) (Table 1). As indicated in bold in Table 1 all
primer and probes contained two to four CpG dinucle-
otides, to ensure specific detection of methylated DNA. A
standard curve of bisulfite-treated DNA of SiHa was
included in each qMSP. As negative controls, H2O,
unmodified genomic DNA obtained from SiHa cells and
unmethylated DNA obtained from primary keratinocytes
were included. The house keeping gene β-actin was
included as a quality control (Table 1) [40,41]. qMSP
reactions were carried out in a 12 μl reaction volume con-
taining 50 ng of bisulfite-treated DNA, 417 nM of each
primer, 208 nM probe and 1× QuantiTect Probe PCR Kit
master mix (Qiagen, Westburg, Leusden, The Nether-
lands) using the ABI 7500 Fast Real-Time PCR System
(Applied Biosystems, Nieuwerkerk a/d IJssel, The Neth-
erlands). For each qMSP assay the threshold was fixed at
0.01. All samples analysed in the study showed an ACTB
CT value that was equal to or below 31 (CT ≤ 31). qMSP
values of target genes were adjusted for DNA input by
expressing the results as ratios between the absolute tar-
get measurement and the ACTB measurement (mean
quantity of methylated hTERT DNA/mean DNA quantity
for β-actin * 1000).
All samples were tested in duplicate and in case of dis-
crepancy (in < 10% of cases) in quadruplicate. Samples
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Sequence primers/
Location
Sequences
hTERT S1/-442 to -219 F 5' GGGTTATTTTATAGTTTAGGT 3'
R 5' AATCCCCAATCCCTC 3'
hTERT S2/-208 to +104 F 5' GTTTTGTTTTTTTATTTTTTAGTTT 3'
R 5' CCAACCCTAAAACCCCAAA 3'
hTERT S3/+88 to +348 F 5' TTTGGGGTTTTAGGGTTGG-3'
R 5' AACCACCAACTCCTTCAAA-3'
hTERT S4/+319 to +566 F 5' GTAGGTGTTTTGTTTGAAGGA-3'
R 5' TACCAACAAATAAACCAAC-3'
MSP primers/
Location
Sequences*
hTERT M1/-317 to -262 F 5' TAGATTTTCGGGTTCGTTCG 3'
R 5' TCTATACCCGCGAATCCACT 3'
P 5' CGACCTAACCCCGACAACGCAACTA 3'
hTERT M2/+288 to +419 F 5' GAGTAGCGTAGGCGATTTAGGGCGT 3'
R 5' GTCCAACAACGCGAAACCGAA 3'
P 5' CGCACAACCTCTACAACACTCGAACCACCAACTC 3'
β actin F 5' TGGTGATGGAGGAGGTTTAGTAAGT 3'
R 5' AACCAATAAAACCTACTCCTCCCTTAA 3'
P 5' ACCACCACCCAACACACAATAACAAACACA 3'
*Methylation specific CpGs are printed in bold
scored positive if at least two test results (quantity ratios)
were above zero.
Results
hTERT mRNA expression and hTERT promoter activity are 
partially correlated
We determined hTERT mRNA expression by real time
RT-PCR in primary keratinocytes (EK cells), HPV-
immortalized cell lines and cervical carcinoma cell lines
SiHa, HeLa, and CaSki. The cell line Saos-2 was included
as an hTERT negative control. The HPV-immortalized
cell lines comprised two HPV16-transfected keratinocyte
cell lines (FK16A and FK16B) and two HPV18-trans-
fected keratinocyte cell lines (FK18A and FK18B). Even-
tually cell lines became immortal and gained strong
telomerase activity, but were not yet tumorigenic in nude
mice [29,33]. As shown in Figure 1A, hTERT mRNA was
undetectable in Saos-2 cells and present at very low levels
in primary keratinocytes (0.2). Relatively high hTERT
mRNA levels were detected in all HPV-immortalized cell
lines and cervical carcinoma cell lines, with hTERT
mRNA levels ranging from 1.2 to 9.1, relative to the
housekeeping gene PBGD.
To investigate hTERT promoter activity in these cells,
we measured luciferase expression of construct hTERT-
297/-23, containing hTERT promoter sequences from -
297 to -23, relative to the ATG. hTERT promoter activi-
ties were related to the CMV-promoter activity in the
pGL3 control vector, which was set at 100%. The relative
hTERT promoter activity was 3% in Saos-2 cells and 5% in
EK cells (Figure 1B). Relative levels of hTERT promoter
activity in in vitro immortalized cells and cancer cells
ranged from 5% in HeLa cells to 37% in FK16A cells (Fig-
ure 1B). However, relative levels of promoter activity did
not always correlate with relative hTERT mRNA levels.
Promoter activity in EK and Saos-2 cells was comparable
to that in HeLa cells (Figure 1B), despite the fact that
hTERT mRNA levels were markedly higher in HeLa cells
(Figure 1A).
Repression of hTERT promoter activity by sequences 
flanking the hTERT core promoter
To examine the contribution of sequences located 5' and
3' of the hTERT core promoter to hTERT promoter activ-
ity, we tested the reporter constructs hhhhTERT-1821/-
23, hTERT-499/-23, hTERT-297/+81, and hTERT-297/
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core promoter construct in the various cell lines.
Insertion of 5' sequences, i.e. -499 to -23 (hTERT -499/-
23) resulted in a strong reduction in luciferase activity,
varying from 45% in HeLa cells to 82% in FK16B and
FK18A cells. Also in primary keratinocytes and telom-
erase negative Saos-2 cells, luciferase activity was
strongly repressed, indicating that the repression is cell
type-independent. Insertion of additional upstream pro-
moter sequences starting at -1821 (hTERT-1821/-23) did
generally not further suppress the promoter activity, indi-
cating that the suppressive effect can mainly be attributed
to sequence -499 to -297, relative to ATG. The repression
of core promoter activity upon inclusion of both
5'sequences is shown in Figure 2B, in which the luciferase
activity of both constructs relative to the hTERT-297/-23
core promoter construct is depicted.
Inclusion of sequences downstream of the core pro-
moter encompassing part of the first exon up to nucle-
otide +81 (hTERT-297/+81), also repressed the basal
luciferase activity, which varied from an 18% reduction in
FK18B cells to a 67% decrease in SiHa cells (Figure 2C). A
further, very strong repression of promoter activity was
seen upon addition of sequences up to +357, spanning
the first exon, first intron and part of exon 2 (hTERT-297/
+357). The resulting reduction in promoter activity
ranged from 85% in Saos-2 cells to 96% in FK16B, SiHa
and CaSki cells. The repression of core promoter activity
upon inclusion of both 3'sequences is shown in Figure 2C
by plotting luciferase activity of both constructs relative
to the hTERT-297/-23 core promoter construct.
Conclusively, our findings indicate that both the -499 to
-297 region and core promoter downstream exonic/
intronic sequences up to +357 contain putative repressive
regulatory sequences.
hTERT bisulfite sequencing analysis in cultured cells
Since in telomerase positive cells the suppressive effect of
sequences flanking the core promoter seems to be
released, we reasoned that this might be due to epigenetic
differences. This view is supported by studies that show a
correlation between hTERT promoter methylation and
hTERT transcription [11,14,39]. We therefore deter-
mined the methylation status of the putative hTERT reg-
ulatory sequences identified in the transient expression
assays. By bisulfite sequencing we analyzed CpG methy-
lation of the region spanning nucleotides -442 to +566,
relative to the ATG in primary keratinocytes (EK), FK16A
and SiHa cells. Using overlapping PCR products the fol-
lowing 4 regions were analyzed: -442 to -219 bp (region
S1), -208 to +104 bp (region S2), +88 to +348 bp (region
S3), and +319 to +566 bp (region S4), all relative to the
ATG site (Figure 3A).
Throughout the promoter, except for region S2, few
methylated CpGs were detected in EK cells. Compared to
these primary cells, methylation was increased in the
HPV16-immortalized cell line FK16A at all four regions.
An even higher methylation level was found in S1, S3 and
S4 from SiHa cells. An overview of the distribution and
frequency of methylated CpGs in individual alleles in EK,
FK16A and SiHa is shown in Figure 3B.
To determine whether methylation occurs at specific
transcription factor binding sites, the known CpG over-
lapping binding sites were plotted at the top of Figure 3A.
A rather random distribution of methylated CpGs relative
to these sites was evident within region S1 and S2 (Figure
3B, top panels). Interestingly, the presence of a so-called
unmethylated core, including the CpGs -19 to -12, which
has been described to contribute to hTERT expression by
others [17,42], was not observed in the hTERT expressing
cells. Within region S3 methylation of FK16A and SiHa
cells was mainly concentrated at the 3' end. The 3' sub-
region preferentially affected by methylation in these cell
lines, contains putative binding sites for the transcription
factors AP2, AP4 and MYOD [10]) (Figure 3B, lower left
panel). Methylation at region S4 was most extensive in
Figure 1 hTERT mRNA expression and core promoter activity in 
all cell cultures. (A) hTERT mRNA levels relative to the housekeeping 
gene PBGD and (B) hTERT core promoter activity as assessed by the 
hTERT-297/-23 reporter construct. Given values are percentages of lu-
ciferase activity relative to pGL3 control that was set at 100%.
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right panel). Interestingly, within this region the lowest
methylation was seen at the second CTCF binding site
(CpG 54-56) in all cells analyzed. However, at the first
CTCF binding site located within region S2, methylation
was slightly increased (Figure 3B, lower right panel).
Next to these three cell cultures, the remaining three
HPV-immortalized cell lines (FK16B, FK18A and FK18B)
as well as the cervical cancer cell lines HeLa and CaSki
were subjected to bisulfite sequencing analysis of the S3
and S4 region. Similar to FK16A and SiHa cells, it was
found that all remaining three HPV-immortalized cell
lines and the two cervical cancer cell lines showed a high
density of methylated CpGs in these two regions com-
pared to primary keratinocytes. Moreover, in SiHa,
FK16A and FK16B cells methylation at the 3'end of the S3
region was particularly high.
A summary of CpG methylation frequencies in regions
S1 to S4 is shown in Table 2.
hTERT bisulfite sequencing analysis in clinical specimens
In addition to the cell lines, DNA from four hrHPV-posi-
tive cervical scrapings, classified as normal cytology (n =
2), borderline or mild dyskaryosis (n = 1) and moderate
dyskaryosis (n = 1), respectively, as well as a cervical car-
cinoma biopsy were analyzed by bisulfite sequencing at
regions S3 and S4. An overview of methylation of individ-
ual CpGs and locations of transcription factor binding
sites is shown in Figure 3C. Methylation frequencies in
region S3 and S4 are summarized in Table 3.
Methylation levels in clinical specimens were generally
lower than in cell cultures, most likely resulting from the
admixture of normal cells in these samples. Only at S3 an
increase in methylation was detected proportional to
increased severity of the cellular abnormality (Figure 3C,
lower left panel). If present, methylation within region S3
tended to be highest at both the 5'and 3' ends, which
together cover putative AP2, AP4 and MYOD binding
sites, as mentioned above [10]. Although methylation of
the S4 region was not increased in the cancer specimen
compared to the normal specimens, it was, when present,
concentrated at the 3' end of the region (Figure 3C, lower
right panel).
Thus, increased methylation of particularly the S3
region, spanning +88 to +348, was associated with malig-
nant transformation both in vitro and in vivo. This partic-
Figure 2 hTERT promoter activity analysis, using hTERT reporter constructs carrying different promoter and proximal exonic sequences. 
(A) Schematic representation of different reporter constructs used. (B) Luciferase activity in Saos-2, EK04-3, FK16A, FK16B, FK18A, FK18B, SiHa, HeLa and 
CaSki cells following transfection of hTERT-1821/-23 and hTERT-499/-23, relative to hTERT-297/-23 that was set at 100%. (C) Luciferase activity in Saos-
2, EK04-3, FK16A, FK16B, FK18A, FK18B, SiHa, HeLa and CaSki following transfection of hTERT-297/+81 and hTERT-297/+357, relative to hTERT-297/-23 
that was set at 100%.
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Figure 3 Bisulfite sequencing results of hTERT regulatory regions. (A) Schematic overview of the four regions analyzed: S1: -442 to -219, S2:-208 
to +104, S3: +88 to +348, and S4:+319 to +566. Numbers refer to the respective CpG dinucleotides and their position relative to the ATG. The positions 
of transcription factor binding sites, if containing CpG dinucleotides, are shown at the top by the black lines (or grey lines when located directly next 
to each other). Regions analyzed by qMSP (M1 and M2) are indicated by dotted lines. (B) CpG methylation results of individual cloned PCR products 
of cultured cells (EK cells, FK16A cells, and SiHa cells). (C) CpG methylation results of individual cloned PCR products of clinical specimens (cervical 
scraping classified as normal (Pap1), borderline mild dyskaryosis (BMD, Pap2/3a1), moderate dyskaryosis (Pap3a2), and a cervical squamous cell carci-
noma (SCC)). Of all samples ten representative clones are shown. Unmethylated CpGs are indicated by grey squares and methylated CpGs are indi-
cated by black squares.
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Page 9 of 14ular region resides in the fragment that displayed the
strongest repressive effect on the core promoter activity
in the transient expression assays.
qMSP analysis of the hTERT promoter and first exon
To further assess the hTERT methylation status in cervi-
cal tissue specimens, we designed two quantitative meth-
ylation-specific PCRs (qMSPs). With primer design
restrictions taken into account, these qMSPs encom-
passed sequences that showed increased methylation in
immortalized cell lines and/or severe cervical disease, as
found by bisulfite sequencing; i.e. one within the proxi-
mal promoter region (M1: -317 to -262) and a second
within the gene (M2: +288 to +419) (Figure 3A).
For validation we tested primary keratinocytes (EK94-
2), having a very low hTERT mRNA expression and little
methylation as assessed by bisulfite sequencing, and
HPV-immortalized and cervical cancer cell lines with ele-
vated hTERT mRNA levels and methylation of the
hTERT CpG island, i.e. FK16A, FK16B, FK18A, FK18B,
SiHa, HeLa and CaSki. In line with the bisulfite sequenc-
ing results, primary keratinocytes were negative by qMSP
at both regions, while all hTERT-positive cell lines, except
CaSki, were qMSP-positive at both regions. CaSki tested
negative at region M1 (Figure 4). In clinical specimens,
methylation at M1 was detected in 14% (3/22) of normal
controls, 17% (4/23) of CIN1 lesions, 48% (13/27) of
CIN3 lesions, and in all (20/20) SCCs (Figure 4). M2
methylation was found in 27% (6/22) of normal controls,
42% (11/26) of CIN1 lesions, 69% (20/29) of CIN3 lesions,
and all (20/20) SCCs (Figure 4). Methylation at both
regions was found in 5% (1/22) of normal controls, 9% (2/
23) of CIN1 lesions, 38% (11/27) of CIN3 lesions, and
100% (20/20) of SCCs (Figure 4).
At both regions the level of methylation increased with
the severity of cervical disease (Figure 5). Thus, not only
the number of samples positive for methylation
increased, but also the degree of methylation per sample
increased with stage of disease.
Discussion
Deregulated hTERT expression, resulting in the activa-
tion of telomerase, is a critical event during hrHPV-
induced transformation, and is likely to mark a so-called
point of no return during cervical carcinogenesis. To fur-
ther elucidate the mechanisms underlying hTERT dereg-
ulation in HPV-transformed cells, both hTERT promoter
activity and DNA methylation alterations were assessed
in HPV-immortalized cells and cervical cancer cell lines
as well as cervical (pre)cancerous lesions.
Using reporter constructs, we found that hTERT core
promoter activity correlated to endogenous mRNA
expression in most, though not all, cell lines. If hTERT
expression is regulated mainly by transcription factor
binding to the core promoter, reporter activity is
expected to be correlated with endogenous hTERT
expression. Our findings indicate, however, that
sequences flanking the core promoter, particularly those
spanning -499 to -297 and +88 to +348 (all relative to the
ATG), inhibit basal hTERT promoter activity in HPV-
immortalized cells and cervical carcinoma cell lines.
Transcriptional repression by 5' sequences is in accor-
dance with previous studies using cancer cell lines
[6,7,37]. Transcriptional repressors with binding sites in
this promoter distal region include WT1 (-358) [43], SP1
(-358, -323, +254) [44], EGR1 (-358) [45], and CTCF (+4)
[18]. The latter two bind the hTERT promoter in cervical
cancer cells [18,45]. Although transcriptional repression
by sequences downstream of the core promoter confirms
previous results, it cannot be completely ruled out that
the reduced promoter activity of the hTERT-297/+357
Table 2: Percentage of methylation in cultured primary keratinocytes, HPV-immortalized cell lines and cervical carcinoma 
cell lines
Cell culture %methylation (total number of clones analyzed)
S1
(-442/-219)
S2
(-208/+104)
S3
(+88/+348)
S4
(+319/+566)
EK 9 (20) 29 (20) 0 (15) 6 (22)
FK16A 27(20) 53 (20) 26 (13) 47 (18)
SiHa 51(20) 53 (20) 45 (15) 83 (22)
FK16B 27 (16) 40 (16)
FK18A 40 (16) 38 (24)
FK18B 21 (13) 41 (20)
HeLa 18 (12) 29 (21)
CaSki 65 (6) 93 (20)
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luciferase gene [37].
The partial disparity between endogenous hTERT
expression and exogenous hTERT promoter activity
prompted us to assess whether differences in epigenetic
factors, particularly DNA methylation, may regulate
hTERT expression in HPV-transformed cell lines, as was
observed in other cell lines [11-18,39,42,46-48]. Most,
though not all, studies found a positive correlation
between hTERT methylation and hTERT expression.
By extensive bisulfite sequencing of HPV-transfected
keratinocyte cell lines, a gradual increase in DNA methy-
lation with progression from a mortal phenotype (repre-
sented by primary keratinocytes), via an immortal
phenotype (represented by the HPV-immortalized cells)
to a tumorigenic phenotype (represented by cervical can-
cer cells) was observed (Figure 3). Also in HPV-positive
cervical samples representing (pre)malignant disease, an
increase in methylation with progression of disease was
detected at 2 of the 3 regions analyzed. Overall, methyla-
tion was less extensive in clinical specimens than in cell
lines, which may be explained either by selection of cells
containing methylated hTERT during culturing and/or
the presence of normal cells in clinical specimens.
Remarkably, within region S3, containing exon 1, meth-
ylation was more abundant at putative binding sites for
AP2, AP4 and MYOD [10]. As binding of AP2 can be
inhibited by methylation [49], it is likely that binding of
AP4 and MYOD is also methylation-sensitive. Although
the beta isoform of AP2 activates hTERT transcription
Table 3: Percentage of methylation in hrHPV-positive cervical scrapings and a cervical carcinoma
Cervical specimen % methylation (number of clones analyzed)
S3 S4
Normal cytology, hrHPV+ 1 (23) 10 (24)
Normal cytology, hrHPV+ 1(25) 11(25)
Borderline mild dyskaryosis, hrHPV+ 3 (20) 8 (20
Moderate dyskaryosis, hrHPV+ 13 (20) 8 (20)
Cervical carcinoma, HPV16+ 17 (20) 7 (20)
Figure 4 Quantitative methylation-specific PCR (qMSP) results for two regions of the hTERT gene. Results of both cell cultures and cervical tis-
sue biopsies are shown. Region M1 spans nts -317 to -262 bp, relative to the ATG and region M2 spans nt +288 to +219 bp, relative to the ATG. Black 
boxes indicate methylation positive, gray boxes indicate no methylation and white boxes remain undetermined. HPV status of specimens is depicted 
as specific HPV type present or negative (-).
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Figure 5 Association between methylation and disease stage. Scatter plots with on the y-axes levels of methylated DNA, on the x-axes the sam-
ples grouped for each disease stage (Note that only positive samples are given). (A) Region M1: -317 to -262 bp, relative to the ATG. (B) Region M2: 
+288 to +219 bp, relative to the ATG.
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parts also contain AP2 binding sites, of which some may
act repressive by means of other AP2 family-members
(AP2α, γ, δ, ε).
Renaud et al. demonstrated that the methylation-sensi-
tive repressor CTCF has two binding sites in the 5'end of
hTERT, located at +4 to +39 and +422 to +440 (both rela-
tive to the ATG) [18]. Like in various human cancer cell
lines and primary tumors, including HeLa cells and a cer-
vical carcinoma [42], we also observed increased methy-
lation of the first CTCF site in HPV-transformed cell
lines and cervical SCC (Figure 3). However, the second
CTCF site is less densily methylated than the surrounding
sequences, implying that many alleles may still be able to
recruit CTCF. Whether inhibition of CTCF binding to
only the first site derepresses hTERT during HPV-medi-
ated transformation remains to be determined. The high
levels of methylation at both CTCF binding sites as
detected in HeLa cells by Guilleret et al. [39], could not
be confirmed in our studies, a feature that may be due to
different HeLa subclones that were used [51].
Similar to CTCF, the transcriptional repressor Egr-1
binds to a CpG containing sequence located at -358 in the
hTERT promoter (Figure 3). Interestingly, although Egr-1
acts as a transcriptional repressor of hTERT promoter-
driven reporter constructs in cervical cancer cell lines,
Egr-1 expression is elevated in hTERT positive cervical
carcinomas [45]. Thus also the repressive activity of Egr-1
may be inhibited by DNA methylation in cervical cancer
cells and contribute to hTERT expression, because in
approximately half of the alleles in the HPV-immortalized
cell lines and cervical cancer cell lines, the Egr-1 site was
methylated (Figure 3A, CpG -42 - -46).
Recent studies have reported that although the hTERT
promoter and coding sequence are frequently methylated
in human tumors, a hypomethylated region around the
transcription start site is believed to be sufficient to allow
transcription [17,42]. Specific CpGs that were found to
remain unmethylated in these studies are CpG -20 to
CpG -12 [42] and CpG -19 to +14 [17]. Although we also
observed only partial methylation around the transcrip-
tion start site (at -58 bp from the ATG, between CpG -7
and -8), methylation was not decreased compared to the
surrounding regions analyzed. In fact, in the SCCs we
observed more methylation in region S2, spanning CpG -
24 to +15, than in the two downstream regions. However,
since the methylation patterns we observed are heteroge-
neous and dynamic, the unmethylated or partially unm-
ethylated alleles may be expressed, as was suggested by
Zinn et al. [17]. Support for this comes from the finding
that active histone marks were particularly associated
with unmethylated DNA and inactive histone marks gen-
erally, though less pronounced, with methylated DNA
[17].
To assess the potential diagnostic value of hTERT
methylation we performed qMSP analysis on a region in
the hTERT promoter (-330 to -260 bp) and a second
region in the first intron and second exon (+290 to +420
bp). With progression to cervical cancer a gradual
increase in methylation was observed. Methylation at
either the first or the second region was found in a rela-
tively high percentage of normal controls (14% and 27%,
respectively) and CIN1 lesions (17% and 37%, respec-
tively). Together with the fact that hTERT mRNA expres-
sion is only rarely elevated in normal cervical cells and
low grade cervical lesions [21,52], these findings may
indicate that generally, methylation of both regions rather
than either region is associated with deregulated hTERT
expression.
Although to the best of our knowledge there are no
reports on hTERT methylation in the complete spectrum
of cervical squamous lesions, hTERT promoter methyla-
tion as detected by qMSP analysis using primers span-
ning -280 to -160 bp, relative to the ATG, has been
detected in almost 60% of cervical carcinomas and none
of normal cervical tissues [53]. The fact that we observed
increased methylation of both regions analyzed in a
marked subset of precursor lesions and in all cervical car-
cinomas indicates that hTERT methylation analysis may
be of diagnostic value for the triage of hrHPV-positive
women. Since past studies have shown that both telom-
erase activity and hTERT mRNA and protein levels in
cervical scrapings only poorly reflect the status of these
markers in the underlying lesions [54-57], hTERT methy-
lation may be an attractive alternative marker.
Conclusions
We demonstrated that CpG methylation of transcription-
ally repressive sequences in the hTERT promoter and
proximal exonic sequences is correlated to deregulated
hTERT transcription in HPV-immortalized cells and cer-
vical cancer cells. Analysis of cervical biopsies represent-
ing the full spectrum of cervical disease revealed that the
detection of DNA methylation at these repressive regions
may provide an attractive biomarker for early detection of
cervical cancer.
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